Van de Velde Sarah, Van Bergen Tine, Vandewalle Evelien, Kindt Nele, Castermans Karolien, Moons Lieve, Stalmans Ingeborg
Laboratory of Ophthalmology, KU Leuven, Leuven, Belgium.
Laboratory of Ophthalmology, KU Leuven, Leuven, Belgium; Department of Ophthalmology, University Hospitals Leuven (UZ Leuven), Leuven, Belgium.
Prog Brain Res. 2015;220:283-97. doi: 10.1016/bs.pbr.2015.04.014. Epub 2015 Jun 30.
First, to elucidate the effect of Rho kinase inhibitor, AMA0526, on Human Tenon Fibroblast (HTF) proliferation and transdifferentiation to myofibroblasts. Second, the effects of ROCK inhibition on the wound healing process and surgical outcome were investigated in a rabbit model of glaucoma filtration surgery.
After exposure of HTF to AMA0526 (0.1-25 μM), a water-soluble tetrazolium salt-1 assay and caspase 3/7 activity assay were used to assess its effect on cell proliferation and to elucidate any toxic effects, respectively. Immunohistochemistry of α-smooth muscle actin expression was used to investigate fibroblast-to-myofibroblast differentiation induced by transforming growth factor-beta 1 (TGF-β1) in the presence or absence of the ROCK inhibitor. The effect of topical treatment was studied in a rabbit model of glaucoma filtration surgery. Treatment outcome was studied by performing intraocular pressure (IOP) measurements and clinical investigation of the bleb area and survival. Immunohistological analysis for inflammation (CD45), angiogenesis (CD31), and collagen I was performed at day 8, 14, and 30 after surgery (n=5/time point). Separate control groups treated with vehicle were used as control.
In vitro results showed that AMA0526 dose dependently inhibited proliferation of HTF (P<0.05) without the induction of caspase 3/7 activity. Incubation of HTF with the AMA0526 inhibited TGF-β1 induced fibroblast-to-myofibroblast differentiation. In the rabbit model, topical treatment significantly improved surgical outcome. Compared to vehicle-treated eyes, AMA0526 resulted in increased bleb area (P<0.0001) and prolonged survival (P=0.0025). IOP remained significantly lower throughout the course of the experiment in the AMA0526 group (P<0.0001). Histological evaluation revealed that blebs treated with the ROCK inhibitor were characterized by reduced inflammation, angiogenesis, and collagen deposition at the site of filtration surgery (P<0.05).
AMA0526 had profound effects on HTF proliferation and myofibroblast transition and improved glaucoma filtration surgery outcome by interfering at different levels of the wound healing process. Therefore, these data indicate that ROCK inhibitors may be considered as more physiological agents which specifically target the wound healing process to improve the outcome of glaucoma surgery.
第一,阐明Rho激酶抑制剂AMA0526对人Tenon成纤维细胞(HTF)增殖及向肌成纤维细胞转分化的影响。第二,在兔青光眼滤过手术模型中研究ROCK抑制对伤口愈合过程及手术效果的影响。
将HTF暴露于AMA0526(0.1 - 25 μM)后,分别采用水溶性四氮唑盐-1检测法和半胱天冬酶3/7活性检测法评估其对细胞增殖的影响并阐明任何毒性作用。在有或无ROCK抑制剂存在的情况下,利用α-平滑肌肌动蛋白表达的免疫组织化学法研究转化生长因子-β1(TGF-β1)诱导的成纤维细胞向肌成纤维细胞的分化。在兔青光眼滤过手术模型中研究局部治疗的效果。通过测量眼压(IOP)以及对滤过泡面积和存活情况进行临床研究来评估治疗效果。在术后第8、14和30天(每个时间点n = 5)对炎症(CD45)、血管生成(CD31)和I型胶原进行免疫组织学分析。使用单独用赋形剂处理的对照组作为对照。
体外实验结果显示,AMA0526剂量依赖性地抑制HTF增殖(P < 0.05),且未诱导半胱天冬酶3/7活性。HTF与AMA0526共同孵育可抑制TGF-β1诱导的成纤维细胞向肌成纤维细胞的分化。在兔模型中,局部治疗显著改善了手术效果。与赋形剂处理的眼睛相比,AMA0526使滤过泡面积增加(P < 0.0001)且存活时间延长(P = 0.0025)。在整个实验过程中,AMA0526组的眼压仍显著较低(P < 0.0001)。组织学评估显示,用ROCK抑制剂处理的滤过泡在滤过手术部位的炎症、血管生成和胶原沉积减少(P < 0.05)。
AMA0526对HTF增殖和肌成纤维细胞转变有显著影响,并通过干扰伤口愈合过程的不同水平改善了青光眼滤过手术效果。因此,这些数据表明ROCK抑制剂可被视为更具生理性的药物,其特异性靶向伤口愈合过程以改善青光眼手术效果。